Overview

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Treatments:
Everolimus
Lenvatinib
Trametinib